ID   LS411N
AC   CVCL_1385
SY   LS-411N; LS-411; LS 411; LS411
DR   CLO; CLO_0007406
DR   CLO; CLO_0009968
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-2159
DR   BioGRID_ORCS_Cell_line; 935
DR   BioSample; SAMN03472557
DR   BioSample; SAMN10988286
DR   cancercelllines; CVCL_1385
DR   Cell_Model_Passport; SIDM00660
DR   ChEMBL-Cells; CHEMBL3308268
DR   ChEMBL-Targets; CHEMBL2366189
DR   ColonAtlas; LS411
DR   Cosmic; 685868
DR   Cosmic; 887215
DR   Cosmic; 907794
DR   Cosmic; 948862
DR   Cosmic; 985999
DR   Cosmic; 995401
DR   Cosmic; 1043821
DR   Cosmic; 1310951
DR   Cosmic; 1312306
DR   Cosmic; 1479613
DR   Cosmic; 1995491
DR   Cosmic; 2301999
DR   Cosmic; 2760088
DR   Cosmic; 2800575
DR   Cosmic-CLP; 907794
DR   DepMap; ACH-000985
DR   EGA; EGAS00001000978
DR   GDSC; 907794
DR   GEO; GSM513913
DR   GEO; GSM514300
DR   GEO; GSM741269
DR   GEO; GSM887280
DR   GEO; GSM888355
DR   GEO; GSM1006219
DR   GEO; GSM1006220
DR   GEO; GSM1006221
DR   GEO; GSM1346848
DR   GEO; GSM1374637
DR   GEO; GSM1448140
DR   GEO; GSM1670061
DR   IARC_TP53; 21479
DR   IARC_TP53; 21751
DR   LiGeA; CCLE_191
DR   LINCS_LDP; LCL-1337
DR   MetaboLights; MTBLS227
DR   PharmacoDB; LS411N_863_2019
DR   PRIDE; PXD005235
DR   PRIDE; PXD005354
DR   PRIDE; PXD005355
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1385
DR   PubChem_Cell_line; CVCL_1385
DR   SKY/M-FISH/CGH; 5011
DR   Wikidata; Q54903069
RX   PubMed=1389533;
RX   PubMed=1617643;
RX   PubMed=8464898;
RX   PubMed=8895552;
RX   PubMed=10737795;
RX   PubMed=11226274;
RX   PubMed=11414198;
RX   PubMed=12068308;
RX   PubMed=16418264;
RX   PubMed=16854228;
RX   PubMed=18258742;
RX   PubMed=19927377;
RX   PubMed=20164919;
RX   PubMed=20570890;
RX   PubMed=20606684;
RX   PubMed=22460905;
RX   PubMed=23272949;
RX   PubMed=23932154;
RX   PubMed=24755471;
RX   PubMed=25926053;
RX   PubMed=25984343;
RX   PubMed=26537799;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=28854368;
RX   PubMed=29101300;
RX   PubMed=29444439;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=31068700;
RX   PubMed=31395879;
RX   PubMed=31978347;
RX   PubMed=35839778;
WW   https://www.cellosaurus.org/pawefish/ColonCellLineDescriptions/LS411.html
WW   https://tcpaportal.org/mclp/
CC   Part of: AstraZeneca Colorectal cell line (AZCL) panel.
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: TCGA-110-CL cell line panel.
CC   Population: Caucasian.
CC   Doubling time: 23 hours (PubMed=25984343); 24 hours (ATCC=CRL-2159).
CC   HLA typing: A*02:40,30:01; B*18:01,56:01; C*01:02,07:06; DQA1*03:02,05:02; DQB1*03:02,03:02; DRB1*11:04,13:47 (PubMed=26589293).
CC   Microsatellite instability: Instable (MSI-high) (PubMed=24755471; PubMed=25926053; PubMed=31068700; Sanger).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln789Ter (c.2365C>T); ClinVar=VCV000092341; Zygosity=Heterozygous (PubMed=24755471; ATCC; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (PubMed=24755471; ATCC; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (PubMed=12068308; PubMed=20570890; PubMed=24755471; ATCC; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Cys105Valfs*8 (c.313delT); ClinVar=VCV000940879; Zygosity=Heterozygous (PubMed=24755471; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys164Argfs*3 (c.491delA); ClinVar=VCV000189448; Zygosity=Heterozygous (PubMed=24755471; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (PubMed=16418264; PubMed=24755471; Cosmic-CLP; DepMap).
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Deep quantitative phosphoproteome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: miRNA expression profiling.
CC   Omics: N-glycan profiling.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: shRNA library screening.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=1.71%; Native American=0%; East Asian, North=2.86%; East Asian, South=0%; South Asian=7.57%; European, North=27.91%; European, South=59.95% (PubMed=30894373).
CC   Derived from site: In situ; Cecum; UBERON=UBERON_0001153.
ST   Source(s): ATCC; Cosmic-CLP; PubMed=25926053
ST   Amelogenin: X
ST   CSF1PO: 10 (PubMed=25926053)
ST   CSF1PO: 10,11 (ATCC; Cosmic-CLP)
ST   D13S317: 12,13,14 (Cosmic-CLP; PubMed=25926053)
ST   D13S317: 12,13,14,16 (ATCC)
ST   D16S539: 11,12
ST   D21S11: 29,32,34
ST   D5S818: 9,15 (Cosmic-CLP)
ST   D5S818: 9,15,16,17 (ATCC)
ST   D5S818: 9,16 (PubMed=25926053)
ST   D7S820: 7.3,9.3 (ATCC; PubMed=25926053)
ST   D7S820: 8,10 (Cosmic-CLP)
ST   TH01: 6
ST   TPOX: 8,9
ST   vWA: 15,16 (Cosmic-CLP)
ST   vWA: 15,16,17 (ATCC)
ST   vWA: 16,17 (PubMed=25926053)
DI   NCIt; C5543; Cecum adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   32Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 42
//
RX   PubMed=1389533; DOI=10.1016/0959-8049(92)90031-V;
RA   Lahm H., Petral-Malec D., Yilmaz-Ceyhan A., Fischer J.R.,
RA   Lorenzoni M., Givel J.-C., Odartchenko N.;
RT   "Growth stimulation of a human colorectal carcinoma cell line by
RT   interleukin-1 and -6 and antagonistic effects of transforming growth
RT   factor beta 1.";
RL   Eur. J. Cancer 28:1894-1899(1992).
//
RX   PubMed=1617643;
RA   Suardet L., Gaide A.-C., Calmes J.-M., Sordat B., Givel J.-C.,
RA   Eliason J.F., Odartchenko N.;
RT   "Responsiveness of three newly established human colorectal cancer
RT   cell lines to transforming growth factors beta 1 and beta 2.";
RL   Cancer Res. 52:3705-3712(1992).
//
RX   PubMed=8464898; DOI=10.1073/pnas.90.7.2842;
RA   Browning M.J., Krausa P., Rowan A.J., Bicknell D.C., Bodmer J.G.,
RA   Bodmer W.F.;
RT   "Tissue typing the HLA-A locus from genomic DNA by sequence-specific
RT   PCR: comparison of HLA genotype and surface expression on colorectal
RT   tumor cell lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:2842-2845(1993).
//
RX   PubMed=8895552; DOI=10.1002/(SICI)1097-0215(19960927)68:1<126::AID-IJC22>3.0.CO;2-8;
RA   Suardet L., Li C., Little J.B.;
RT   "Radio-induced modulation of transforming growth factor beta1
RT   sensitivity in a p53 wild-type human colorectal-cancer cell line.";
RL   Int. J. Cancer 68:126-131(1996).
//
RX   PubMed=10737795; DOI=10.1073/pnas.97.7.3352;
RA   Rowan A.J., Lamlum H., Ilyas M., Wheeler J., Straub J.,
RA   Papadopoulou A., Bicknell D.C., Bodmer W.F., Tomlinson I.P.M.;
RT   "APC mutations in sporadic colorectal tumors: a mutational 'hotspot'
RT   and interdependence of the 'two hits'.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:3352-3357(2000).
//
RX   PubMed=11226274; DOI=10.1073/pnas.041603298;
RA   Abdel-Rahman W.M., Katsura K., Rens W., Gorman P.A., Sheer D.,
RA   Bicknell D.C., Bodmer W.F., Arends M.J., Wyllie A.H., Edwards P.A.W.;
RT   "Spectral karyotyping suggests additional subsets of colorectal
RT   cancers characterized by pattern of chromosome rearrangement.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:2538-2543(2001).
//
RX   PubMed=11414198; DOI=10.1007/s004320000207;
RA   Lahm H., Andre S., Hoeflich A., Fischer J.R., Sordat B., Kaltner H.,
RA   Wolf E., Gabius H.-J.;
RT   "Comprehensive galectin fingerprinting in a panel of 61 human tumor
RT   cell lines by RT-PCR and its implications for diagnostic and
RT   therapeutic procedures.";
RL   J. Cancer Res. Clin. Oncol. 127:375-386(2001).
//
RX   PubMed=12068308; DOI=10.1038/nature00766;
RA   Davies H., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S.,
RA   Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N.,
RA   Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J.,
RA   Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S.,
RA   Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S.,
RA   Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J.,
RA   Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A.,
RA   Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T.,
RA   Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R.,
RA   Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.;
RT   "Mutations of the BRAF gene in human cancer.";
RL   Nature 417:949-954(2002).
//
RX   PubMed=16418264; DOI=10.1073/pnas.0510146103;
RA   Liu Y., Bodmer W.F.;
RT   "Analysis of P53 mutations and their expression in 56 colorectal
RT   cancer cell lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:976-981(2006).
//
RX   PubMed=16854228; DOI=10.1186/1476-4598-5-29;
RA   Bandres E., Cubedo E., Agirre X., Malumbres R., Zarate R., Ramirez N.,
RA   Abajo A., Navarro A., Moreno I., Monzo M., Garcia-Foncillas J.;
RT   "Identification by real-time PCR of 13 mature microRNAs differentially
RT   expressed in colorectal cancer and non-tumoral tissues.";
RL   Mol. Cancer 5:29.1-29.10(2006).
//
RX   PubMed=18258742; DOI=10.1073/pnas.0712176105;
RA   Emaduddin M., Bicknell D.C., Bodmer W.F., Feller S.M.;
RT   "Cell growth, global phosphotyrosine elevation, and c-Met
RT   phosphorylation through Src family kinases in colorectal cancer
RT   cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:2358-2362(2008).
//
RX   PubMed=19927377; DOI=10.1002/gcc.20730;
RA   Knutsen T., Padilla-Nash H.M., Wangsa D., Barenboim-Stapleton L.,
RA   Camps J., McNeil N.E., Difilippantonio M.J., Ried T.;
RT   "Definitive molecular cytogenetic characterization of 15 colorectal
RT   cancer cell lines.";
RL   Genes Chromosomes Cancer 49:204-223(2010).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20570890; DOI=10.1158/0008-5472.CAN-10-0192;
RA   Janakiraman M., Vakiani E., Zeng Z.-S., Pratilas C.A., Taylor B.S.,
RA   Chitale D., Halilovic E., Wilson M., Huberman K., Ricarte Filho J.C.M.,
RA   Persaud Y., Levine D.A., Fagin J.A., Jhanwar S.C., Mariadason J.M.,
RA   Lash A., Ladanyi M., Saltz L.B., Heguy A., Paty P.B., Solit D.B.;
RT   "Genomic and biological characterization of exon 4 KRAS mutations in
RT   human cancer.";
RL   Cancer Res. 70:5901-5911(2010).
//
RX   PubMed=20606684; DOI=10.1038/sj.bjc.6605780;
RA   Bracht K., Nicholls A.M., Liu Y., Bodmer W.F.;
RT   "5-fluorouracil response in a large panel of colorectal cancer cell
RT   lines is associated with mismatch repair deficiency.";
RL   Br. J. Cancer 103:340-346(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23272949; DOI=10.1186/1755-8794-5-66;
RA   Schlicker A., Beran G., Chresta C.M., McWalter G., Pritchard A.,
RA   Weston S., Runswick S., Davenport S., Heathcote K., Castro D.A.,
RA   Orphanides G., French T., Wessels L.F.A.;
RT   "Subtypes of primary colorectal tumors correlate with response to
RT   targeted treatment in colorectal cell lines.";
RL   BMC Med. Genomics 5:66.1-66.15(2012).
//
RX   PubMed=23932154; DOI=10.1016/j.radonc.2013.06.032;
RA   Salendo J., Spitzner M., Kramer F., Zhang X., Jo P., Wolff H.A.,
RA   Kitz J., Kaulfuss S., Beissbarth T., Dobbelstein M., Ghadimi M.,
RA   Grade M., Gaedcke J.;
RT   "Identification of a microRNA expression signature for
RT   chemoradiosensitivity of colorectal cancer cells, involving
RT   miRNAs-320a, -224, -132 and let7g.";
RL   Radiother. Oncol. 108:451-457(2013).
//
RX   PubMed=24755471; DOI=10.1158/0008-5472.CAN-14-0013;
RA   Mouradov D., Sloggett C., Jorissen R.N., Love C.G., Li S.,
RA   Burgess A.W., Arango D., Strausberg R.L., Buchanan D., Wormald S.,
RA   O'Connor L., Wilding J.L., Bicknell D.C., Tomlinson I.P.M., Bodmer W.F.,
RA   Mariadason J.M., Sieber O.M.;
RT   "Colorectal cancer cell lines are representative models of the main
RT   molecular subtypes of primary cancer.";
RL   Cancer Res. 74:3238-3247(2014).
//
RX   PubMed=25926053; DOI=10.1038/ncomms8002;
RA   Medico E., Russo M., Picco G., Cancelliere C., Valtorta E., Corti G.,
RA   Buscarino M., Isella C., Lamba S., Martinoglio B., Veronese S.,
RA   Siena S., Sartore-Bianchi A., Beccuti M., Mottolese M.,
RA   Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.;
RT   "The molecular landscape of colorectal cancer cell lines unveils
RT   clinically actionable kinase targets.";
RL   Nat. Commun. 6:7002.1-7002.10(2015).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
//
RX   PubMed=26537799; DOI=10.1074/mcp.M115.051235;
RA   Holst S., Deuss A.J.M., van Pelt G.W., van Vliet S.J.,
RA   Garcia-Vallejo J.J., Koeleman C.A.M., Deelder A.M., Mesker W.E.,
RA   Tollenaar R.A., Rombouts Y., Wuhrer M.;
RT   "N-glycosylation profiling of colorectal cancer cell lines reveals
RT   association of fucosylation with differentiation and caudal type
RT   homebox 1 (CDX1)/villin mRNA expression.";
RL   Mol. Cell. Proteomics 15:124-140(2016).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=28854368; DOI=10.1016/j.celrep.2017.08.010;
RA   Roumeliotis T.I., Williams S.P., Goncalves E., Alsinet C.,
RA   Del Castillo Velasco-Herrera M., Aben N., Ghavidel F.Z., Michaut M.,
RA   Schubert M., Price S., Wright J.C., Yu L., Yang M., Dienstmann R.,
RA   Guinney J., Beltrao P., Brazma A., Pardo M., Stegle O., Adams D.J.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Choudhary J.S.;
RT   "Genomic determinants of protein abundance variation in colorectal
RT   cancer cells.";
RL   Cell Rep. 20:2201-2214(2017).
//
RX   PubMed=29101300; DOI=10.15252/msb.20177701;
RA   Frejno M., Zenezini Chiozzi R., Wilhelm M., Koch H., Zheng R.-S.,
RA   Klaeger S., Ruprecht B., Meng C., Kramer K., Jarzab A., Heinzlmeir S.,
RA   Johnstone E., Domingo E., Kerr D., Jesinghaus M., Slotta-Huspenina J.,
RA   Weichert W., Knapp S., Feller S.M., Kuster B.;
RT   "Pharmacoproteomic characterisation of human colon and rectal
RT   cancer.";
RL   Mol. Syst. Biol. 13:951-951(2017).
//
RX   PubMed=29444439; DOI=10.1016/j.celrep.2018.01.051;
RA   Yuan T.L., Amzallag A., Bagni R., Yi M., Afghani S., Burgan W.,
RA   Fer N., Strathern L.A., Powell K., Smith B., Waters A.M., Drubin D.A.,
RA   Thomson T., Liao R., Greninger P., Stein G.T., Murchie E., Cortez E.,
RA   Egan R.K., Procter L., Bess M., Cheng K.T., Lee C.-S., Lee L.C.,
RA   Fellmann C., Stephens R., Luo J., Lowe S.W., Benes C.H.,
RA   McCormick F.;
RT   "Differential effector engagement by oncogenic KRAS.";
RL   Cell Rep. 22:1889-1902(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31395879; DOI=10.1038/s41467-019-11415-2;
RA   Yu K., Chen B., Aran D., Charalel J., Yau C., Wolf D.M.,
RA   van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.;
RT   "Comprehensive transcriptomic analysis of cell lines as models of
RT   primary tumors across 22 tumor types.";
RL   Nat. Commun. 10:3574.1-3574.11(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//